O'Neal W - Search Results

1

Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

Nasser A, Kosheleff AR, Hull JT, Liranso T, Qin P, Busse GD, O'Neal W, Fava M, Faraone SV, Rubin J. Nasser A, et al. J Child Adolesc Psychopharmacol. 2021 Apr;31(3):214-226. doi: 10.1089/cap.2020.0148. Epub 2021 Feb 17. J Child Adolesc Psychopharmacol. 2021. PMID: 33600233 Free PMC article. Clinical Trial.

2

Real-world assessment of treatment with extended-release topiramate (Trokendi XR^®) and comparison with previous immediate-release topiramate treatment.

O'Neal W, Hur EE, Liranso T, Patel B. O'Neal W, et al. J Comp Eff Res. 2018 Nov;7(11):1095-1105. doi: 10.2217/cer-2018-0074. Epub 2018 Aug 23. J Comp Eff Res. 2018. PMID: 30136603 Free article.

3

Closing the gap: unmet needs of individuals with impulsive aggressive behavior observed in children and adolescents.

Robb AS, Connor DF, Amann BH, Vitiello B, Nasser A, O'Neal W, Schwabe S, Ceresoli-Borroni G, Newcorn JH, Candler SA, Buitelaar JK, Findling RL. Robb AS, et al. CNS Spectr. 2021 Oct;26(5):448-456. doi: 10.1017/S1092852920001224. Epub 2020 Mar 31. CNS Spectr. 2021. PMID: 32228725 Review.

4

Predicted Efficacy of Once-Daily Extended-Release Oxcarbazepine (Oxtellar XR^®) Monotherapy in Adults and Children with Partial-Onset Seizures: Exposure-Response Modeling and Simulation.

Faison S, Gomeni R, Mendes S, O'Neal W, Schwabe S, Nasser A. Faison S, et al. Clin Pharmacol. 2020 Sep 23;12:135-147. doi: 10.2147/CPAA.S256972. eCollection 2020. Clin Pharmacol. 2020. PMID: 33061671 Free PMC article.

5

Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.

Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Faraone SV, et al. Psychiatry Res. 2021 Feb;296:113664. doi: 10.1016/j.psychres.2020.113664. Epub 2021 Jan 5. Psychiatry Res. 2021. PMID: 33418457 Free article.

6

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.

Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH. Findling RL, et al. CNS Drugs. 2021 Jun;35(6):643-653. doi: 10.1007/s40263-021-00825-w. Epub 2021 May 18. CNS Drugs. 2021. PMID: 34003459 Free PMC article. Review.

7

The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder.

Nasser A, Gomeni R, Wang Z, Hull JT, Busse GD, Melyan Z, Fava M, O'Neal W, Rubin J. Nasser A, et al. Br J Clin Pharmacol. 2022 Nov;88(11):4828-4838. doi: 10.1111/bcp.15412. Epub 2022 Jun 8. Br J Clin Pharmacol. 2022. PMID: 35588245 Free PMC article.

8

Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.

Faraone SV, Gomeni R, Hull JT, Chaturvedi SA, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Faraone SV, et al. Psychiatry Res. 2022 Dec;318:114922. doi: 10.1016/j.psychres.2022.114922. Epub 2022 Oct 23. Psychiatry Res. 2022. PMID: 36375329 Free article. Clinical Trial.

9

Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.

Cutler AJ, Mattingly GW, Jain R, O'Neal W. Cutler AJ, et al. CNS Spectr. 2022 Apr;27(2):199-207. doi: 10.1017/S1092852920001984. Epub 2020 Oct 30. CNS Spectr. 2022. PMID: 33121553 Review.

10

CHP2 Modifies Chronic Pseudomonas aeruginosa Airway Infection Risk in Cystic Fibrosis.

Faino AV, Gordon WW, Buckingham K, Stilp AM, Pace RG, Raraigh KS, Collaco JM, Zhou YH, Dang H, O'Neal W, Knowles MK, Cutting GR, Rosenfeld M, Bamshad MJ, Gibson RL, Blue EE; Cystic Fibrosis Genome Project. Faino AV, et al. Among authors: o neal w. Ann Am Thorac Soc. 2025 Jan 2. doi: 10.1513/AnnalsATS.202408-868OC. Online ahead of print. Ann Am Thorac Soc. 2025. PMID: 39746161

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

416 results

Search Page

Filters